Fondaparinux
From Ganfyd
rINN: Fondaparinux
Other Names
Arixtra®
Pharmacological Information
Pharmacology Images
Web information on Fondaparinux
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Medpedia on Fondaparinux (Less technical, good quality control)
Wikipedia on Fondaparinux (Less technical, ? quality control)
Contents |
Introduction
Selective inhibitor of factor Xa
Clinical Use
Indications
- Acute coronary syndrome in those not undergoing primary percutaneous coronary intervention[1][2]
- Venous thromboembolism in elective orthopedic patients
- Adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis[3]
Administration
- S/C 2.5 mg once daily in ACS
Clinical Issues
Contra-indications
Cautions and Interactions
Side effects
Special advice
The use of fondaparinux in treating superficial vein thrombosis (superficial phlebitis) to prevent more serious VTE does not make economic sense in any health economy at 2010 prices[4].
References
- ↑ Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA : the journal of the American Medical Association. 2006 Apr 5; 295(13):1519-30.(Link to article – subscription may be required.)
- ↑ Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. The New England journal of medicine. 2006 Apr 6; 354(14):1464-76.(Link to article – subscription may be required.)
- ↑ Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B, Laporte S, Matyas L, Middeldorp S, Sokurenko G, Leizorovicz A. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. The New England journal of medicine. 2010 Sep 23; 363(13):1222-32.(Link to article – subscription may be required.)
- ↑ Goldman L, Ginsberg J. Superficial phlebitis and phase 3.5 trials. The New England journal of medicine. 2010 Sep 23; 363(13):1278-80.(Link to article – subscription may be required.)
